CCR5 is a gene that provides instructions for building a protein on the surface of certain immune cells. This protein acts as a docking port, helping guide immune cells to sites of infection and inflammation. It gained widespread attention because HIV exploits this same protein to break into and infect immune cells, and a naturally occurring mutation in the gene can make people resistant to the virus.
The gene sits on chromosome 3 and encodes what’s known as a chemokine receptor, a protein embedded in the outer membrane of T cells and macrophages (two key players in immune defense). Under normal circumstances, CCR5 responds to chemical signals called chemokines that direct immune cell movement throughout the body. But its role as an entry point for HIV has made it one of the most studied genes in modern medicine.
How HIV Uses CCR5 To Infect Cells
HIV doesn’t just latch onto any cell. To get inside, the virus needs to bind to two separate proteins on the cell surface. First, it attaches to a receptor called CD4. That initial contact causes a structural change in the virus’s outer coat, exposing a region called the V3 loop. This loop then reaches out and grabs onto CCR5, which serves as the second docking point. Only after both connections are made can the virus fuse with the cell membrane and inject its genetic material.
Not all strains of HIV use CCR5. Some use a different co-receptor called CXCR4, and some can use either one. The strains that rely on CCR5 are called R5-tropic viruses, and they’re the most common type transmitted between people. This distinction matters for treatment: a drug that blocks CCR5 only works against R5-tropic strains, so doctors must run a tropism test to identify which type of virus a patient carries before prescribing a CCR5-blocking medication.
The Delta 32 Mutation and HIV Resistance
A naturally occurring variant of the CCR5 gene, called CCR5-delta 32, is missing 32 base pairs of DNA. This deletion produces a shortened, nonfunctional version of the protein that never reaches the cell surface. People who inherit two copies of this mutation (one from each parent) essentially have no working CCR5 receptors on their immune cells. Without that second docking point, R5-tropic HIV has no way in.
The mutation is unevenly distributed across the globe. It appears in roughly 10% of people of European descent, with the highest concentrations (above 15%) around the Baltic Sea, the White Sea, and central Russia. Outside of Europe, it’s rare. The global average is about 3%. In East and Southeast Asian populations, Native Americans, sub-Saharan Africans, and Pacific Islanders, the mutation is virtually absent. In Asian countries overall, the frequency sits around 2%.
Carrying one copy of the mutation (being heterozygous) doesn’t provide complete HIV resistance, but it may slow disease progression. Carrying two copies (being homozygous) provides strong, though not absolute, protection against R5-tropic strains.
Stem Cell Transplants That Cured HIV
The most dramatic demonstration of CCR5’s role in HIV came from patients who were effectively cured of the virus after receiving stem cell transplants from donors with two copies of the delta 32 mutation. These transplants were performed to treat blood cancers, not HIV itself, but the replacement of the patient’s immune system with one lacking functional CCR5 had an extraordinary side effect: the virus could no longer infect new cells, and the existing viral reservoir was eliminated.
More recently, a case published in Nature showed that even a transplant from a donor with just one copy of the delta 32 mutation could lead to sustained remission. The patient stopped antiretroviral therapy three years after transplant and remained free of detectable virus for over six years. Researchers found no replication-capable HIV in blood or intestinal tissue samples. This case suggests that complete absence of CCR5 isn’t strictly necessary for a cure, and that effective reduction of the viral reservoir plays a critical role alongside CCR5 status.
These cases aren’t a scalable treatment. Stem cell transplants carry serious risks, including graft-versus-host disease, and are only performed when a patient has a life-threatening condition like leukemia that independently requires one. But they proved the concept that targeting CCR5 could eliminate HIV.
CCR5-Blocking Medication
The understanding of how HIV uses CCR5 led to the development of a drug that blocks the receptor. This medication works by binding inside CCR5’s pocket and changing its shape so that HIV’s outer coat protein can no longer latch on. It’s the only approved drug in its class and is used in combination with other antiretroviral medications.
Because the drug only blocks one of HIV’s two possible entry routes, it’s ineffective against virus strains that use the CXCR4 receptor or a mix of both. A tropism assay is required before starting treatment to confirm the patient carries R5-tropic virus. For patients with the right viral profile, the drug adds another layer of suppression to their regimen.
Tradeoffs of Missing CCR5
People born without functional CCR5 appear generally healthy, which initially suggested the protein was expendable. But research has revealed that losing CCR5 comes with specific vulnerabilities. The most striking involves West Nile virus. In a study of patients with confirmed West Nile infections, people homozygous for the delta 32 mutation were significantly more likely to develop severe, symptomatic disease. The odds of a fatal outcome were roughly 13 times higher in homozygous carriers compared to people with normal CCR5 function.
This makes biological sense. CCR5 helps recruit immune cells to sites of infection in the brain and other tissues. Without it, the immune response to certain viruses is delayed or weakened. The same concern applies to patients taking CCR5-blocking drugs: by mimicking the genetic defect, the medication could theoretically increase vulnerability to West Nile and potentially other infections where CCR5-mediated immune signaling is important.
CCR5 and Brain Recovery
Beyond infectious disease, CCR5 has an unexpected role in the brain. Research has found that reducing CCR5 activity improves recovery after stroke and traumatic brain injury. In animal models, suppressing CCR5 preserved the tiny connections between brain cells, promoted new neural wiring patterns, and activated signaling pathways associated with learning and memory. In a large clinical study of stroke patients, people who naturally carried the delta 32 mutation showed greater recovery of both neurological function and cognitive ability compared to those with normal CCR5.
This finding reframes CCR5 as more than an immune system gene. It appears to act as a kind of brake on brain plasticity, and removing that brake after injury allows the brain to rewire more effectively. This line of research has prompted interest in whether CCR5-blocking drugs already used for HIV could be repurposed to improve outcomes after stroke or head injuries.
The CRISPR Controversy
In November 2018, Chinese scientist He Jiankui announced that he had used the CRISPR gene-editing tool to modify the CCR5 gene in human embryos, resulting in the birth of twin girls. He claimed to have given them lifetime immunity to HIV by recreating the delta 32 mutation.
The reality was far messier. Analysis of his own data revealed that neither twin actually received the delta 32 mutation. Instead, the edits produced novel mutations in CCR5 that had never been observed in any human population, meaning their effects on HIV resistance and overall health were completely unknown. One of the twins, referred to as Lulu, had only one edited copy of the gene alongside a completely normal copy, which would have offered little to no HIV protection even if the edit had been correct. He knew this before implanting the embryos.
The experiment was widely condemned as reckless. The potential benefits were overstated, the execution was flawed, and the risks to the children were unquantifiable. He Jiankui was sentenced to three years in prison. The case became a defining moment in the debate over heritable human gene editing, illustrating both the allure and the dangers of manipulating a gene whose full range of functions, from immune defense to brain recovery to vulnerability to other infections, is still being mapped.